Given that ferroptosis-related therapies have emerged as promising anti-cancer treatment strategies, with several FDA-approved drugs already available, such as sorafenib, sulfasalazine, statins, and artemisinin [6, 47, 48], we believe that developing small-molecule drugs targeting the LAPTM4B-SLC7A11 axis holds significant clinical potential. This evidence concerns the gene SLC7A11 and cancer.